In contrast, patients with lower SLC44A2 expression in pancreatic adenocarcinoma (PAAD), invasive breast carcinoma (BRCA), and adrenocortical carcinoma (ACC) had better OS than those with higher SLC44A2 expression (Fig. S1D). Here, SLC44A2 is linked to invasive breast carcinoma.